Video Series: Current Topics in the Treatment of Advanced PCa

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Latest Prostate Cancer Features

MRI/US Fusion Improves Prostate Cancer Detection

MRI/US Fusion Improves Prostate Cancer Detection

The approach can help identify suitable candidates for active surveillance, but false positives and cost effectiveness are concerns.

Latest Prostate Cancer News

Prostate Biopsy May Be Avoidable if MRI Findings Are Negative

Prostate Biopsy May Be Avoidable if MRI Findings Are Negative

In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.

Adverse Effects of Treatment for Localized PCa Clarified

Adverse Effects of Treatment for Localized PCa Clarified

Findings from 2 new studies could enable more informed patient counseling about choice of therapy.

Nerve-sparing RP May Not Raise Positive Margin Risk

Nerve-sparing RP May Not Raise Positive Margin Risk

Researchers found no evidence of worse cancer outcomes with nerve-sparing surgery.

TRT Does Not Appear to Increase PCa Risk

TRT Does Not Appear to Increase PCa Risk

A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).

Bone Metastases Seldom Progress During Radium-223 Therapy

Bone Metastases Seldom Progress During Radium-223 Therapy

At 6 months of treatment, bone imaging showed stable disease in 94% of patients with available data, study finds.

Prostate MRI Quality May Improve With Bowel Prep

Prostate MRI Quality May Improve With Bowel Prep

In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.

Targeted Biopsy Detects Gleason Score Upgrading in AS

Targeted Biopsy Detects Gleason Score Upgrading in AS

Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.

Researchers Identify mCRPC Drug Sequence Offering the Best Survival

Researchers Identify mCRPC Drug Sequence Offering the Best Survival

In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.

Urologists Support Targeted Biopsy

Urologists Support Targeted Biopsy

In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.

Prostate Cancer Treatment Prolongs Survival

Prostate Cancer Treatment Prolongs Survival

Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.

Higher BMI Lowers Death Risk in Men With Advanced Prostate Cancer

Higher BMI Lowers Death Risk in Men With Advanced Prostate Cancer

In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.

Black Patients May Be Adversely Affected by Less PSA Screening

Black Patients May Be Adversely Affected by Less PSA Screening

Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.

Sign up for free e-Newsletters